PURPOSE/ OBJECTIVE: To assess the interaction of HPV/p16 status and therapy rendered in patients with locally advanced squamous cell carcinoma of the larynx and hypopharynx. MATERIALS AND METHODS: Forty-seven consecutive patients receiving definitive treatment between 2009 and 2011 for locally advanced larynx or hypopharynx cancer with high-risk HPV and/or p16 testing performed were identified and retrospectively investigated. Overall survival (OS), disease-free survival (DFS), and local recurrence-free survival (LRFS) were assessed. RESULTS: Of 47 evaluable patients, there were 38 (81%) with laryngeal and 9 (19%) with hypopharyngeal tumors, 13 (28%) of which were found to be either HPV or p16 positive. At a median follow-up of 24 months, comparing HPV/p16+ versus HPV/p16- patients, there was no difference in OS, DFS, or LRFS. There was an improvement in 2-year DFS (60% vs 100%, P=.03) and LRFS (80% vs 100%, P=.08), in HPV/p16+ patients treated with chemo/RT versus surgery. There was an improvement in 2-year DFS (100% vs 68%, P=.04) and LRFS (100% vs 72%, P=.05) in HPV/p16+ versus HPV/p16- patients who received chemo/RT. CONCLUSIONS: Patients with HPV/p16+ tumors fared more favorably with chemo/RT than up-front surgery, with improvements in DFS and LRFS. In patients treated with the intent of organ preservation therapy, HPV/p16+ patients had no observed treatment failures. HPV/p16 status should be taken into account when considering organ preservation for locally advanced larynx and hypopharynx cancers.
PURPOSE/ OBJECTIVE: To assess the interaction of HPV/p16 status and therapy rendered in patients with locally advanced squamous cell carcinoma of the larynx and hypopharynx. MATERIALS AND METHODS: Forty-seven consecutive patients receiving definitive treatment between 2009 and 2011 for locally advanced larynx or hypopharynx cancer with high-risk HPV and/or p16 testing performed were identified and retrospectively investigated. Overall survival (OS), disease-free survival (DFS), and local recurrence-free survival (LRFS) were assessed. RESULTS: Of 47 evaluable patients, there were 38 (81%) with laryngeal and 9 (19%) with hypopharyngeal tumors, 13 (28%) of which were found to be either HPV or p16 positive. At a median follow-up of 24 months, comparing HPV/p16+ versus HPV/p16- patients, there was no difference in OS, DFS, or LRFS. There was an improvement in 2-year DFS (60% vs 100%, P=.03) and LRFS (80% vs 100%, P=.08), in HPV/p16+ patients treated with chemo/RT versus surgery. There was an improvement in 2-year DFS (100% vs 68%, P=.04) and LRFS (100% vs 72%, P=.05) in HPV/p16+ versus HPV/p16- patients who received chemo/RT. CONCLUSIONS:Patients with HPV/p16+ tumors fared more favorably with chemo/RT than up-front surgery, with improvements in DFS and LRFS. In patients treated with the intent of organ preservation therapy, HPV/p16+ patients had no observed treatment failures. HPV/p16 status should be taken into account when considering organ preservation for locally advanced larynx and hypopharynx cancers.
Authors: Huaising C Ko; Paul M Harari; Ryan M Sacotte; Shuai Chen; Aaron M Wieland; Menggang Yu; Andrew M Baschnagel; Justine Y Bruce; Randall J Kimple; Matthew E Witek Journal: J Cancer Res Clin Oncol Date: 2017-07-27 Impact factor: 4.553
Authors: Hong Li; Sina J Torabi; Wendell G Yarbrough; Saral Mehra; Heather A Osborn; Benjamin Judson Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-06-01 Impact factor: 6.223
Authors: Lars Sivars; Cinzia Bersani; Nathalie Grün; Torbjörn Ramqvist; Eva Munck-Wikland; Christian Von Buchwald; Tina Dalianis Journal: Mol Clin Oncol Date: 2016-10-13
Authors: Shama Virani; Emily Bellile; Carol R Bradford; Thomas E Carey; Douglas B Chepeha; Justin A Colacino; Joseph I Helman; Jonathan B McHugh; Lisa A Peterson; Maureen A Sartor; Jeremy Mg Taylor; Heather M Walline; Greg T Wolf; Laura S Rozek Journal: BMC Cancer Date: 2015-10-30 Impact factor: 4.430
Authors: Jun Won Kim; Mi Sun Kim; Se-Heon Kim; Joo Hang Kim; Chang Geol Lee; Gwi Eon Kim; Ki Chang Keum Journal: Cancer Res Treat Date: 2015-03-13 Impact factor: 4.679